Navigation Links
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Date:10/14/2010

ly supplemented with calcium and vitamin D.

In the pivotal study, serious infections leading to hospitalizations were reported more frequently in the Prolia-treated patient group. Serious skin infections, as well as infections of the abdomen, urinary tract and ear, were more frequent in patients treated with Prolia. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of severe infection, including cellulitis. Endocarditis was reported more frequently in the Prolia-treated patient group. Epidermal and dermal adverse events such as dermatitis, rashes, and eczema have been reported. Discontinuation of Prolia should be considered if severe symptoms develop.

Prolia resulted in significant suppression of bone remodeling. The significance of these findings is unknown. The long-term consequences of the degree of suppression of bone remodeling observed with Prolia may contribute to adverse outcomes such as osteonecrosis of the jaw (ONJ), atypical fractures, and delayed fracture healing. ONJ has been reported in patients with Prolia. Patients should be monitored for these adverse outcomes. The most common adverse reactions (> 5 percent and more common than placebo) were back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis. Pancreatitis has also been reported with Prolia.

About Denosumab CollaborationsIn July 2009, Amgen and GlaxoSmithKline (GSK) announced a collaboration agreement to jointly commercialize Prolia for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize Prolia's postmenopausal osteoporosis and oncology indications in the U.S. and Canada and for all oncology indications in Europe and in other specified markets.

In addition, GSK will register and commercialize denosumab for all indications in countries where Amgen does not currently have a commercial presence,
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
2. Array BioPharma and Amgen Partner in Type 2 Diabetes
3. Amgen to Present at Lazard Capital Healthcare Conference
4. Amgen Announces Webcast of 2009 Third Quarter Financial Results
5. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
8. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
9. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
10. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
11. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS and NEW YORK ... (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care ... public offering of 3,500,000 shares of common stock, and ... of common stock, at an offering price of $4.00 ... a per share exercise price of $5.00, are exercisable ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... designed to introduce cutting edge communication technology, ... partners of platform upgrades. This webinar series ... users in their quest to leverage web ... According to SoundConnect’s Marketing Manager, Seanna Baumgartner, ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... , , , , , , ... Synthesis with the new Transcriptor Reverse, Transcriptase , ... With the new recombinant ,Transcriptor Reverse Transcriptase, you will , , , ... cDNA transcripts , Reverse transcribe difficult templates with high secondary structure , ...
... , , , , , ... , , Co-transfections , ... DNA constructs work in your cell line. Also, determine the ratio of DNA ,to FuGENE ... ,provides good expression levels. Then, perform the transfection, ensuring the ,DNA / FuGENE 6 Reagent ...
... , , , , ... FuGENE 6 Transfection Reagent in Vector-based shRNA Experiments , ... RNA interference induced by siRNAs or shRNAs allows reliable down-regulation of ... into cells are used directly for transient gene silencing, ,vectors that encode for the ...
Cached Biology Technology:Transcriptor Reverse Transcriptase 2Transcriptor Reverse Transcriptase 3Transcriptor Reverse Transcriptase 4Transcriptor Reverse Transcriptase 5Uses and Applications of FuGENE 6 Transfection Reagent 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... drugs currently studied in clinical trials appears to reduce ... at Georgetown University Medical Center report in an upcoming ... They say the results suggest that this class of ... been able to do-- prevent the long-term and continuing ...
... the specific biological mechanisms believed to lead to ... Diamond Blackfan anemia (DBA). Scientists say with further ... to current thinking about treatment for this disease ... George Thomas, PhD, Stefano Fumagalli, PhD, ...
... or ,gloopiness, of different parts of cancer cells increases ... according to new images that provide fundamental insights into ... today (15 March). The ... cells whilst they are dying as a result of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Cellular discovery may lead to targeted treatment for rare form of anemia 2Cellular discovery may lead to targeted treatment for rare form of anemia 3A sticky business -- how cancer cells become more 'gloopy' as they die 2
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
...
... recognizes 30% of IgM-rheumatoid factor ... does not cross-react with IgM, IgA, ... nor with pooled F(Ab)2 fragments. This ... to detect rheumatoid factor. Product Category: ...
Biology Products: